摘要
In 2013,cancer immunotherapy led the annual breakthroughs in Science.In fact,immunotherapy is one of the hotspots in cancer therapy,and can date back to the Coley vaccine in 1891.Advances in biotechnology and bio-engineering,especially research and development（R＆D）in the fields of therapeutic antibodies,checkpoint inhibitors,and engineered T cells,helped overcome the problems in tumor therapies,leading to increasing research focus on cancer immunotherapy.
In 2013,cancer immunotherapy led the annual breakthroughs in Science.In fact,immunotherapy is one of the hotspots in cancer therapy,and can date back to the Coley vaccine in 1891.Advances in biotechnology and bio-engineering,especially research and development(R&D)in the fields of therapeutic antibodies,checkpoint inhibitors,and engineered T cells,helped overcome the problems in tumor therapies,
基金
supported by the National Key R&D Program(2016YFC1303403)
the Natural and Scientific Foundation of China(81572981,81201789,81672397,81400057)
the National High-tech R&D program(2014AA020704)
